The production of new cell and gene therapies at a manufacturing site in Stevenage – for use in health services around the world – has been given the green light by the Medicines and Healthcare products Regulatory Agency (MHRA).
News
Merck, Pfizer intend to file Bavencio, Inlyta combo
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
Shire’s Veyvondi approved in Europe for bleeding disorder
European regulators have approved Shire’s von Willebrand Disease therapy Veyvondi.
Four new medicines available via NHS Scotland
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
EC green-lights MSD’s Keytruda combo for lung cancer
The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
NICE rejects Opdivo for preventing melanoma recurrence
NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.
NHS moves to clamp down on incorrect/fraudulent prescriptions
A new NHS campaign is striving to clamp down on the millions of pounds worth of prescriptions incorrectly claimed for free each year.
The PharmaTimes Marketer of the Year competition closes for entry this Friday
Now in it’s 25th year, the PharmaTimes Marketer of the Year competition closes for entry on Friday 14th September – take advantage of this great opportunity to compete, benchmark, learn and raise standards in pharma marketing.
UK first EU nation to launch flutiform k-haler for asthma
Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma.
AstraZeneca, Amgen’s tezepelumab wins ‘breakthrough’ status
AstraZeneca and Amgen’s tezepelumab has won breakthrough therapy status in the US for its potential to treat severe asthma without an eosinophilic phenotype.
MS Society launches petition against NICE’s rejection of Ocrevus
The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche to come to an agreement on NHS availability of Ocrevus for primary progressive multiple sclerosis (PPMS).
US regulators reject GSK’s Nucala for COPD
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.
PharmaTimes Sales Awards – last chance to enter!
Entry to the inaugural PharmaTimes Sales Awards – established to recognise and celebrate the very best sales professionals in the industry today – will close today.
BTG buys Irish med device group Novate
Specialist healthcare group BTG has snapped up med tech group Novate Medical in a deal potentially worth $150 million.
Lilly streams £5m into virtual lab pact with UCL, Imperial
Imperial College London, UCL and Eli Lilly have formed an alliance that strives to transform medicines manufacturing in England.
